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Summary
Background: The pathogenesis of autoimmune hepatitis (AIH) is poorly understood 
and little is known about enteric microbiota in AIH.
Aim: To investigate disease-specific microbiome alterations in AIH.
Methods: The V1-V2 variable regions of the 16S rRNA gene were sequenced in fae-
cal samples from 347 patients with AIH and controls (AIH n = 72, healthy controls 
(HC) n = 95, primary biliary cholangitis (PBC) n = 99 and ulcerative colitis (UC) n = 81).
Results: Biodiversity (Shannon entropy) was decreased in AIH patients compared to 
HC (P = 0.016), which was partially reversed by azathioprine (P = 0.011). Regarding 
between-sample diversity, AIH patients separated from HC, PBC and UC individuals 
(all P = 0.001). Compared to HC, decreased relative abundance of anaerobic genera 
such as Faecalibacterium and an increase of Veillonella and the facultative anaerobic 
genera Streptococcus and Lactobacillus were detected. Importantly, a disease-specific 
decline of relative abundance of Bifidobacterium was observed in AIH patients. Lack 
of Bifidobacterium was associated with failure to achieve remission of AIH (P < 0.001). 
Of potential therapeutic implication, Bifidobacterium abundance correlated with av-
erage protein intake (P < 0.001). Random forests classification between AIH and PBC 
on the microbiome signature yielded an area under receiver operating characteristic 
curve (AUC) of 0.787 in the training cohort, and an AUC of 0.849 in an external vali-
dation cohort.
Conclusion: Disease-specific faecal microbial alterations were identified in patients with 
AIH. Intestinal dysbiosis in AIH was characterised by a decline of Bifidobacterium, which 
was associated with increased disease activity. These results point to the contribution of 
intestinal microbiota to AIH pathogenesis and to novel therapeutic targets.
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1 | INTRODUCTION
Autoimmune hepatitis (AIH) is an autoimmune liver disease of un-
known origin.1 If untreated, the disease can rapidly progress to cirrho-
sis and liver failure. Since a causal therapy is lacking, AIH is treated with 
unspecific immunosuppression. Corticosteroids typically serve for in-
duction therapy and azathioprine as a maintenance treatment.1,2 The 
breech of self-tolerance in AIH is poorly understood. Unknown envi-
ronmental triggers may lower the threshold for autoimmune responses 
in vulnerable individuals.1 Dietary ingredients and microorganisms 
represent potential sources of such triggers. The human intestine is 
colonised by a complex community of predominant bacterial microor-
ganisms (‘microbiota’, their genomes termed ‘microbiome’). The enteric 
microbiota is a key regulator of the host’s physiology in health and dis-
ease.3 The liver is engaged in a cross-talk with the intestine (gut–liver 
axis), and is constantly exposed to gut-derived immune cells and micro-
bial products. The ‘strategic’ position of the liver between the portal 
and the systemic circulation highlights its role in translating microbial 
and immune signals originating from the intestine into systemic out-
comes.4 Recently, intestinal microbiome alterations (‘dysbiosis’) were 
reported in patients with AIH and primary biliary cholangitis (PBC), 
pointing towards a possible link between microbiome alterations and 
autoimmune liver diseases.5,6 In a Chinese cohort, disease-associated 
dysbiosis in untreated patients with AIH was characterised by reduced 
biodiversity, decreased abundance of anaerobes and increase of the 
genera Veillonella, Klebsiella, Streptococcus and Lactobacillus.5 However, 
it remains unclear whether this microbial signature is specific com-
pared to other autoimmune liver diseases or other immune-mediated 
diseases, and whether it is reproducible across geographic borders. In 
the present study, a comprehensive analysis of the luminal microbiota 
was performed in patients with AIH in comparison to healthy controls 
(HC), patients with PBC and ulcerative colitis (UC), an inflammatory 
bowel disease with well-defined dysbiosis.
2  | METHODS
2.1 | Study cohort
AIH and PBC were diagnosed based on clinical, biochemical, serological 
and histological criteria (the latter are not generally required for PBC) 
according to the most recent guidelines.2,7 All AIH patients received a 
liver biopsy at initial diagnosis. All patients with AIH and PBC under-
went treatment and regular follow-up at the University Medical Center 
Hamburg-Eppendorf, Germany. Patients were followed-up for at least 
12 months after stool collection. Therefore, the diagnosis of AIH or 
PBC was unequivocal in all cases. In order to assess disease-specific 
microbial alterations, patients with variant syndromes (formerly 
termed ‘overlap-syndromes’, such as AIH/PBC or AIH/primary scleros-
ing cholangitis) were excluded from the analysis. HC and UC patients 
were recruited by the PopGen Biobank (Institute of Epidemiology, 
Kiel, Germany). The diagnosis of UC was established based on medi-
cal history, exclusion of infectious colitis and colonoscopy with biopsy 
according to the most recent guidelines.8 UC patients with concurrent 
liver disease were excluded. Eligible samples from 347 participants 
(AIH n = 72, PBC n = 99, UC n = 81, HC n = 95) were available (detailed 
description provided in Table 1). All study participants in the discovery 
cohort lived in Northern Germany for several years. Patients with AIH 
(n = 10) or PBC (n = 15) from an independent cohort were enrolled at 
the University Hospital Munich, Germany (clinical patient character-
istics given in Table 2). Comprehensive biometric, lifestyle and medi-
cal data were retrieved from a questionnaire and medical records and 
validated by a physician. Blood parameters and transient elastography, 
as a surrogate for liver fibrosis, were measured at the time of stool 
sampling. Liver stiffness measurement by transient elastography was 
performed using FibroScan (EchoSens, Paris, France). All HC individu-
als underwent screening for factors disqualifying their eligibility as 
controls. Any symptoms and routine laboratory parameters deviating 
from healthy reference ranges, that is CRP ≤5 mg/L, glucose between 
55 and 115 mg/dL and a wide range of diseases covered by a com-
prehensive questionnaire (including diabetes, cancer, respiratory, liver, 
coronary heart disease, heart attack, neuropathy, IBD, IBS, chronic di-
arrhoea, asthma, organ transplantation, phlebitis, varices, and venous 
insufficiency) were criteria for study exclusion. All study participants 
were unrelated individuals. Exclusion criteria for both healthy and dis-
eased participants were age <18 years, decompensated cirrhosis or 
acute liver failure at time of stool collection, concurrent liver disease, 
other severe medical comorbidity, pregnancy and use of antibiotics 
within 6 weeks before stool collection. In AIH patients, full biochemi-
cal remission was defined as normalisation of both transaminase lev-
els and serum IgG levels, according to recent guidelines.2 The study 
protocol was approved by the respective institutional review boards 
(A148/14 and MC-111/15). Written informed consent was obtained 
from all participants.
2.2 | Assessment of dietary data
Dietary data were assessed using a self-administered food fre-
quency questionnaire, which is validated for the German popula-
tion.9 Information on average supply with macro- and micronutrients 
was retrieved using the German Food Code and Nutrient Database,10 
and provided by the German Institute of Human Nutrition, Potsdam-
Rehbrücke, Germany. Complete dietary information was available for 
257 patients (HC n = 85, AIH n = 39, PBC n = 57, UC n = 76).
2.3 | Faecal sample collection and sequencing
A cross-sectional collection of stool samples was performed. 
Standard tubes with DNA stabiliser were used (Stratec Molecular, 
Berlin, Germany). The samples were collected by the participants 
at home and sent to the sequencing facility within 24 hours, where 
they were stored at −80°C until further processing. All faecal sam-
ples were processed and sequenced according to the same standard 
operating procedure at the Institute of Clinical Molecular Biology 
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TA B L E  1   Clinical patient characteristics of the main patient population
 AIH HC PBC UC P-value
Patients (n) 72 95 99 81  
Age, years (median [IQR]) 62.50 [53, 73] 48.00 [37, 55] 61.50 [56, 68.8] 45.00 [35, 54]  < 0.001
Body mass index, kg/m2 (median [IQR]) 24.93 [22.4, 30.1] 22.66 [21.8, 23.8] 26.53 [22.9, 30.6] 24.94 [22.2, 26.7]  < 0.001
Sex, female, n (%) 55 (76.4) 49 (51.6) 90 (90.9) 49 (60.5)  < 0.001
Disease duration, years (median [IQR]) 8.00 [5, 11.3] 0 7.00 [3.3, 10] 11.00 [5, 20] 0.003
Smoking, n (%) 7 (9.7) 0 22 (22.2) 0  < 0.001
Medication at time of stool collection, n (%)
Antibiotics use in last 12 mo 5 (6.9) 0 7 (7.1) 10 (12.3) —
Mesalazine 0 0 0 60 (75.0) —
Sulfasalazine 0 0 0 10 (14.5) —
Budesonide 13 (18.6) 0 3 (3.2) 0 —
Prednisolone 40 (58.0) 0 14 (14.4) 34 (47.2) —
Azathioprine 51 (72.9) 0 6 (6.2) 27 (33.3) —
Mercaptopurine 10 (14.5) 0 0 (0.0) 2 (2.8) —
Infliximab 1 (1.4) 0 3 (3.2) 13 (17.8) —
Mycophenolate 6 (9.7) 0 0 0 —
Ursodeoxycholic acid 2 (3.2) 0 80 (93.0) 0 —
Varices on last gastroscopy, n (%) 9 (12.5) — 3 (3.0) 0 —
Splenomegaly, n (%) 8 (11.1) — 2 (2.0) — —
History of ascites, n (%) 2 (2.8) 0 0 0 —
Fibrosis stage on last biopsy, n (%) (available in n  =  72)  (available in n  =  34)   
0/4 15 (25.0) — 10 (29.4) — —
¼ 8 (13.3) — 14 (41.2) — —
2/4 8 (13.3) — 7 (20.6) — —
3/4 10 (16.7) — 0 — —
4/4 19 (31.7) — 3 (8.8) — —
Transient elastography, kPa (median 
[IQR])
6.00 [4.9, 8.4] — 5.85 [4.8, 6.8] — —
Serum Immunoglobulin G, g/L (median 
[IQR])
12.70 [10.6, 15.1] — 10.90 [9.2, 13.1] — —
Serum bilirubin, mg/dl (median [IQR]) 0.50 [0.4, 0.7] — 0.50 [0.4, 0.5] — —
Serum alanine aminotransferase, U/L 
(median [IQR])
24.00 [20, 30.5] — 25.00 [20, 33] — —
Serum alkaline phosphatase, U/L 
(median [IQR])
68.50 [54.5, 87.8] — 110.00 [86, 135] — —
Serum aspartate aminotransferase, U/L 
(median [IQR])
26.00 [22, 29.5] — 25.00 [21, 28.3] — —
Platelets count, 105/µL (median [IQR]) 265.00 [220, 303.5] — 275.00 [224, 306.3] — —
Serum albumin, mg/dL (median [IQR]) 37.00 [36, 38.8] — 38.25 [37, 39.4] — —
Complete biochemical remission of 
AIH, n (%)
56 (77.8%) — - — —
Presence of serum autoantibodies, n (%)
Anti-nuclear antibodies 69 (95.8) — 53 (57.0) — —
Anti-mitochondrial M2 antibodies 0 (0.0) — 73 (83.0) — —
Smooth muscle antibodies 44 (62.9) — 6 (6.5) — —
Soluble liver antigen antibodies 8 (11.3) — 0 — —
(Continues)
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(Kiel, Germany) as described previously.11 In brief, DNA was ex-
tracted using QIAamp Stool Mini Kit (Qiagen) on a QIAcube system 
with an additional bead-beating step. The variable regions V1-V2 of 
the 16S ribosomal RNA gene were sequenced in a dual-barcode ap-
proach using the primer pair 27F-338R. Sequencing was carried out 
using Illumina MiSeq (Illumina Inc.).
2.4 | Bioinformatic analysis
The ‘dada2’ R package (v1.9.1) was used to infer the ribosomal se-
quence variants (RSVs),12 following the DADA2 workflow for big 
data (benjjneb.github.io/dada2/bigdata_paired.html). Forward and 
reverse reads were trimmed and filtered. Forward reads were trun-
cated to 240 nucleotides and reverse reads to 200 nucleotides. 
Reads with ambiguous bases and more than two expected errors 
were discarded. Chimeric RSVs were removed. Singletons, that is 
RSVs with a singular count, were pruned to reduce bias by rare or 
spurious sequences. Taxonomic annotation was carried out against 
the SILVA database (v132) using the implementation of the naïve 
Bayesian classifier available in DADA2.
2.5 | Statistical analysis
All statistical analyses were carried out with R (v3.5.1). To meas-
ure within-sample diversity (α-diversity), Shannon entropy was 
calculated on Hellinger transformed RSVs abundance matrix 
using the ‘vegan’ package (v2.5.6) functions ‘decostand’ and ‘di-
versity’.13 Chao1 estimated richness was calculated using ‘chao1’ 
function in the ‘fossil’ package (v0.3.7). Biodiversity was modelled 
using least-squares regression (‘stats’ function ‘lm’). To measure 
between-sample diversity (β-diversity), both Bray-Curtis dis-
similarity and Canberra distance were calculated using the vegan 
function ‘vegdist’ on RSV abundance matrix transformed accord-
ing to the geometric mean of pairwise ratios (‘GMPR’ package, 
v0.1.3).14 Both unconstrained ordination by multidimensional 
scaling and constrained ordination were performed using the 
vegan function ‘capscale’. Statistical significance of separation 
among groups was assessed by permutational multivariate analy-
ses of variance (PERMANOVA, ‘vegan’ function ‘adonis’). Pairwise 
differences were tested using ‘pairwise.perm.manova’ function 
in the ‘RVAideMemoire’ package (v0.9-73). Overall differences 
in questionnaire-derived dietary variables were analysed using 
PERMANOVA on Euclidean distance. The ‘envfit’ function in 
‘vegan’ was used to correlate dietary data to microbiome com-
munity composition. Hurdle models with negative binomial dis-
tribution (‘hurdle’ function in the ‘countreg’ package, v0.2.1) 
were used to model single-taxon relative abundances.15 A GMPR 
size-factor was included as an offset to account for differences 
in library size. Statistical significance of model predictors was as-
sessed jointly for the count- and zero-parts using likelihood ratio 
test (‘lrtest’ function in the ‘lmtest’ package, v0.9.37). Dietary 
predictor selection to model single-taxon count abundance was 
carried out using the ‘be.zeroinfl’ function in the ‘mpath’ package 
(v0.3.18). Linear regression, multivariate permutational analysis, 
environmental vector fitting, hurdle models and zero-inflated 
count regression were de-confounded by including body mass 
index, sex, smoking status and use of antibiotics during the past 
12 months as covariables. Predictive modelling with random for-
ests and classifier evaluation were performed using the packages 
‘Boruta’ (v6.0.0) and ‘randomForest’ (4.6.14). Modelling was per-
formed on abundance tables clustered on the genus level and 
rarefied to an even sequencing depth of 10 005 counts. The area 
under the receiver operating characteristic curve (AUC) was 
calculated and tested for statistical significance according to 
Mason and Graham using the ‘roc.area’ function in the ‘verifica-
tion’’ package (v1.42).16 A P < 0.05 was accepted as statistically 
 AIH HC PBC UC P-value
Sp100 nuclear antigen antibodies 0 (0.0) — 19 (21.1) — —
Glycoprotein-210 antibodies 0 (0.0) — 12 (13.3) — —
History of abdominal surgery, n (%) 0 0 0 14 (17.3) —
Dietary variables (median [IQR])









Fibre, g/d 17.81 [14.8, 24.8] 20.08 [16.8, 25.5] 17.94 [13.5, 22.5] 21.66 [17.4, 25.5] 0.010
Protein, g/d 73.76 [55.4, 83.1] 77.32 [63.6, 93.8] 64.88 [54, 75.7] 78.82 [62.5, 97.4]  < 0.001
Fat, g/d 86.36 [69.3, 108.4] 98.03 [79, 122.4] 82.14 [70.3, 95.8] 95.78 [82.5, 
125.1]
0.001




176.30 [132, 220] 242.76 [197.8, 
291.6]
 < 0.001









Differences were assessed for statistical significance using Kruskal-Wallis (unadjusted) nonparametric test.
TA B L E  1   (Continued)
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significant. Multiple testing was controlled by correcting for the 
false-discovery rate (FDR).
3  | RESULTS
3.1 | Reduced enteric microbiota diversity in AIH
We first investigated measures of within-sample biodiver-
sity (α-diversity), which can be indicative for healthy ecosystem 
functioning and resilience. The average Shannon entropy was 
reduced in AIH patients as compared to HC (least-squares re-
gression, P = 0.016). Whereas patients with PBC had an aver-
age Shannon entropy comparable to AIH patients (P = 0.727), 
patients with UC showed a further reduction in enteric mi-
crobial diversity (P < 0.001; Figure 1A). Compared to HC, AIH 
patients had a reduced average estimated richness (Chao1 rich-
ness, P < 0.001), which was similar to PBC and UC patients (both 
P > 0.1; Figure 1B).
3.2 | Disease-specific microbiota alterations in AIH
Between-sample diversity (β-diversity) varied significantly ac-
cording to disease state in the overall analysis (PERMANOVA, 
R2 = 1.76%, P = 0.001) and regarding all pairwise comparisons 
(pairwise PERMANOVA, all FDR = 0.001) on both unconstrained 
(Figure 1C) and constrained ordination (Figure 1D). As expected, 
the microbial communities were mainly composed of three phyla, 
Firmicutes, Bacteroidetes and Proteobacteria. Firmicutes were 
decreased in all diseased groups (median relative abundance, HC: 
48.7%, AIH: 41.9%, PBC: 40.4%, UC: 40.6%; Kruskal-Wallis test, 
P < 0.001). While Bacteroidetes showed no significant differ-
ence between the groups (P = 0.051), Proteobacteria (a phylum 
comprising numerous pathogens) was increased in all diseased 
states (HC: 4.3%, AIH: 6.7%, PBC: 14.1%, UC: 11.4%; P < 0.001; 
Figure 1E).
3.3 | Disease-specific decline of Bifidobacterium 
in AIH
Pairwise differential abundances between the diagnosis groups 
were analysed using zero-truncated negative-binomial hurdle mod-
els (Figure 2A-C). Compared to HC, patients with AIH showed a de-
cline of several genera, including Faecalibacterium (log 2FC = −1.34, 
FDR = 0.021) and Bifidobacterium (log 2FC = −1.89, FDR = 0.021), and 
an increase of Streptococcus (log 2FC = 1.77, FDR = 0.004). Compared 
to PBC, AIH patients showed a greater abundance of Faecalibacterium 
(log 2FC = 2.53, FDR < 0.001), whereas Bifidobacterium showed the 
strongest decrease in AIH (log 2FC = −2.57, FDR < 0.001). In addition, 
we performed a targeted analysis for genera previously reported 
to be relatively enriched in patients with AIH compared to HC 5. 
Klebsiella was not found to be significantly enriched in patients with 
AIH (log 2FC = 0.25, P = 0.490). However, Veillonella (log 2FC = 1.33; 
P = 0.010, FDR = 0.067) and Lactobacillus (log 2FC = 2.43, P = 0.007, 
FDR = 0.060) were validated to be increased in AIH patients but 
did not withstand multiple testing correction. The results for the 
targeted testing based on prior knowledge are shown in Figure 
S1 in Results S1. Comparing AIH vs UC patients, Bifidobacterium 
showed the strongest decline (log 2FC = −1.73, FDR < 0.001). As 
Bifidobacterium was the only genus significantly reduced in AIH pa-
tients across all pairwise comparisons (Figure 2D), we performed a 
TA B L E  2   Clinical patient characteristics of the validation cohort
 AIH PBC P-value
Patients (n) 10 15  
Age, years (median 
[IQR])
62.0 [43, 67] 64.0 [60, 71] 0.36




4.50 [1, 10] 8.0 [4, 13] 0.2
Smoking, n (%) 1 (10) 2 (13.3) 1.0
Medication at time of stool collection, n (%)
Antibiotics use in 
last 12 months
1 (10) 1 (6.7) 1.0
Mesalazine 0 0 —
Sulfasalazine 0 0 —
Budesonide 2 (20) 3 (20) 1.0
Prednisolone 9 (90) 1 (6.7)  < 0.001
Azathioprine 7 (70) 1 (6.7) 0.004
Mercaptopurine 0 0 —
Infliximab 0 0 —




2 (20) 0 0.292
Dietary variables (median [IQR])






































Clinical information available in the PopGen database is given. 
Differences were assessed for statistical significance using Wilcoxon 
rank-sum test (unadjusted).
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targeted analysis on the Bifidobacterium species level. Among the 
bifidobacterial species identified, three species showed a reduced 
abundance in AIH across all group comparisons, Bifidobacterium 
adolescentis (P = 0.007, FDR = 0.051), Bifidobacterium longum 
(P < 0.001, FDR = 0.001) and Bifidobacterium pseudocatenulatum 
(P = 0.014, FDR = 0.084; Figure 2E).
F I G U R E  1   Altered faecal microbiome diversity and composition in AIH. (A) Significantly reduced Shannon entropy and (B) Chao1 
estimated richness in AIH patients. Microbiome community composition was significantly different between AIH patients and both healthy 
and diseased controls regarding (C) multidimensional scaling on Bray-Curtis dissimilarity and (D) constrained ordination on Canberra 
distance. (E) AIH patients and diseased controls showed relatively reduced Firmicutes and increased Proteobacteria levels. AIH: autoimmune 
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HC AIH PBC UC
P < 0.001 P  = 0.051 P  < 0.001
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3.4 | The enteric microbiome accurately 
discriminates AIH
We next investigated whether the faecal microbiota profile can be 
used to discriminate the different autoimmune liver diseases. For 
this purpose, we used random forests. For feature selection, we 
employed an all-relevant feature selection approach termed ‘Boruta’, 
an algorithm which is based on random forests and iteratively re-
moves features which are proved by a statistical test to be less rel-
evant than random probes. Using this approach, six features were 
selected (Figure 3A). Subsequently, a random forest classifier was 
built including these six features on AIH and PBC patients from the 
Hamburg cohort using a number of 9,999 trees, a node size of 1 
and a number of variables at each node (mtry) corresponding to the 
square root of included model features. In the training cohort from 
Hamburg, an AUC of 0.787 (95% CI 0.719-0.855, Mason-Graham 
test, P < 0.001) for the discrimination between AIH and PBC was 
achieved. Bifidobacterium and Faecalibacterium were among the 
most important discriminating features (Figure 3A). The taxonomic 
signature discriminating AIH from PBC was validated using random 
forests in an independent cohort recruited at the University Hospital 
Munich. Validation of the classifier in this cohort yielded an AUC of 
0.849 (95% CI 0.679-1, P = 0.002; Figure 3A-C), indicating robust 
differences between the two autoimmune liver diseases AIH and 
PBC. Moreover, upon classifying between AIH and HC (Figure S2 in 
Results S1), we achieved a comparably accurate classification per-
formance with an average area under the ROC curve of 89.8% upon 
repeated cross-validation.
F I G U R E  2   Differential relative abundance. Genera with significantly different relative distribution comparing (A) AIH vs HC, (B) AIH 
vs PBC and (C) AIH vs UC are displayed by volcano plots. The x-axis shows the log2 fold change, while the y-axis displays the –log 10 
transformed P-value. Genera were considered differentially abundant when reaching an FDR  < 0.05 and absolute log 2 fold change  > 1. 
(D) Strip chart showing differential abundance of Bifidobacterium across all groups. (E) Log-transformed count abundance of individual 
Bifidobacterium species compared across diagnosis groups. AIH, autoimmune hepatitis; FDR, false discovery rate; HC, healthy controls; PBC, 
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3.5 | Associations between diet, Bifidobacterium 
abundance and biochemical remission in AIH
We interrogated a wide array of clinical metadata (Table 1), with 
a particular focus on AIH, for association with microbial features, 
both on the level of overall ecologic indices and relative abundance 
of individual taxa. Questionnaire-derived average consumption 
of macro- and micronutrients did not show statistically significant 
differences between the diagnosis groups adjusting for sex and 
age (PERMANOVA, R2 = 1.82, P = 0.070). We observed no signifi-
cant association between α-diversity and dietary variables (least-
squares regression, all P > 0.1). Adjusting for the diagnosis, average 
protein consumption was identified as a strong positive predic-
tor of Bifidobacterium abundance in the entire cohort (P < 0.001; 
Figure 4A). The strong disease-specific decline of Bifidobacterium in 
AIH was unaffected by adjusting for questionnaire-derived dietary 
items (P < 0.001). On pairwise comparisons, average protein con-
sumption did not differ in AIH patients compared to other groups 
(Wilcoxon test, all P > 0.1). At the time of stool collection, complete 
biochemical remission was achieved by 56 AIH patients (77.8%). 
Biochemical remission status showed no statistically significant 
association with either α-diversity or β-diversity in the AIH cohort 
(both P > 0.1). No significant associations were detected between 
the fibrosis stage on the last liver biopsy and microbial features (all 
P > 0.1). An exploratory analysis was performed to detect associa-
tions between Bifidobacterium and markers of disease activity in 
AIH using zero-inflated count regression. Decreased Bifidobacterium 
levels were associated with an increase of serum IgG (P = 0.024). 
Importantly, Bifidobacterium showed a more pronounced depletion 
in AIH patients who failed to achieve complete biochemical remis-
sion according to recent guidelines (P < 0.001; Figure 4B). As ex-
pected, several dietary variables showed significant association with 
microbiome composition (‘envfit’, Figure 4C). However, this did not 
interfere with the highly significant disease-associated shift in mi-
crobiome composition (PERMANOVA, R2 = 3.17%, P = 0.001).
Of interest, in AIH patients, treatment with azathioprine was 
an independent predictor of increased α-diversity (P = 0.011; 
Figure 4D). This was independent from the presence of biochemical 
remission, pointing towards direct impact of azathioprine on intes-
tinal microbiota or intestinal homeostasis. Such an association was 
not observed in the UC cohort, indicting an AIH-specific effect of 
azathioprine. Budesonide was received by 13 (18.6%) AIH patients, 
and 40 (58.0%) of AIH patients were treated with oral prednisolone. 
However, for both medications, a statistically significant association 
was neither found regarding overall diversity indices nor abundance 
of individual taxonomic markers of AIH (all P > 0.1).
In agreement with a previous report,5 Veillonella abundance was 
positively associated with alanine aminotransferase (ALT) levels in 
AIH patients (P = 0.029; Figure 4E). However, it was not associated 
with overall remission status (P = 0.270), and association with dis-
ease severity was not observed in the PBC cohort. An association 
with dietary variables was not detected for Veillonella.
4  | DISCUSSION
In the present study, a comprehensive analysis of faecal microbial 
alterations was performed in large cohorts of patients with AIH 
F I G U R E  3   The enteric microbiome discriminates between AIH 
and PBC. (A) Feature importance of bacterial genera selected by 
Boruta feature selection algorithm. (B) Random forest classifier 
performance in the training cohort. (C) Random forest classifier 
performance in the Munich validation cohort. The values in brackets 
indicate the 95% confidence interval. AUC, area under the receiver 
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and both healthy and diseased controls. We hereby demonstrated 
that enteric microbiota is distinctly altered in AIH, largely inde-
pendent from multiple clinical and dietary confounders. Moreover, 
the disease-specific decline of Bifidobacterium in AIH was linked 
with failure to achieve remission and may be amenable to dietary 
intervention.
We observed a decline of gut microbial diversity in patients 
compared to HC, which may be associated with loss of beneficial 
functions and ecosystem resilience.17 A bloom of Proteobacteria 
was observed in AIH akin to PBC and UC. Overabundance of 
this phylum is considered an indicator of disturbed host-micro-
biota homeostasis, inflammation and epithelial dysfunction.18 In 
F I G U R E  4   Associations between microbiome, clinical and dietary metadata. (A) Bifidobacterium abundance was associated with average 
protein consumption in the entire cohort. (B) Association between biochemical remission status and Bifidobacterium abundance in the AIH 
cohort. Complete biochemical remission was achieved by 56 AIH patients (77.8%), this association was independent from steroid treatment. 
(C) Correlation between questionnaire-derived dietary variables and gut microbiota configuration in the entire cohort. (D) In the AIH cohort, 
average within-sample (α) diversity was increased in patients treated with azathioprine. (E) Correlation between alanine aminotransferase 
levels and Veillonella abundance in AIH patients. ALT, alanine aminotransferase; R2, percentage of variance in between-sample diversity 
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agreement with a previous study,5 the shift in the enteric micro-
biota of patients with AIH towards a more aerotolerant milieu was 
accompanied by a decline of obligate anaerobic taxa producing 
short-chain fatty acids (SCFAs). SCFA serve as an energy source 
for colonic epithelia and regulate multiple immune responses 
including regulatory T cells.19 In our study, we observed a de-
crease of Faecalibacterium (only known species Faecalibacterium 
prausnitzii) in AIH patients compared to HC. There is an increas-
ing interest in F. prausnitzii due to its well-established anti-in-
flammatory properties, which render the bacterium a promising 
candidate for new-generation probiotic treatment in inflamma-
tory diseases.20 Interestingly, similar to a previous report, we 
detected a relative increase of Veillonella and the facultative an-
aerobes Streptococcus and Lactobacillus.5 Although the increase 
of Veillonella and Lactobacillus was statistically weaker compared 
to the aforementioned study with treatment-naïve patients, our 
finding highlights the stability of AIH-associated dysbiosis across 
geographic areas and after several years of immunosuppressive 
treatment. However, we also clearly demonstrate that these 
microbial alterations were not disease-specific. Nevertheless, 
Veillonella showed a reproducible association with increased ALT 
levels in AIH patients. Animal studies have demonstrated that 
specific pathobionts may increasingly colonise the gut in the con-
text of dysbiosis and drive intestinal or liver inflammation.21,22 
As Veillonella was previously found increased in patients with 
PBC6 and patients with primary sclerosing cholangitis,23,24 it may 
drive hepatic inflammation in autoimmune and cholestatic liver 
diseases.
The bacterial alterations in AIH discussed so far seem to be 
rather unspecific corollaries of chronic inflammation or liver dis-
ease. Nevertheless, we detected a disease-specific decrease of 
Bifidobacterium in AIH patients. The decline of Bifidobacterium was 
associated with failure to achieve biochemical remission. Although 
Bifidobacterium was depleted in AIH independently of diet, higher 
average protein intake may favour its growth, as has been recently 
demonstrated for an amino acid mixture in an animal model.25 
Bifidobacterium species are considered key regulators of gut homeo-
stasis and may exert several health-promoting effects.26 In infants, 
lower intestinal levels of bifidobacteria were prospectively linked to 
the incidence of immunologic disorders, pointing towards a critical 
role of enteric bifidobacteria for immune regulation in humans.27,28 
Recent evidence also suggests that B. longum, B. adolescentis and B. 
pseudocatenulatum (all of which were specifically decreased in AIH) 
attenuate immunologic liver injury in animal models by modulation of 
intestinal homeostasis and enteric microbiota.29-31 It is tempting to 
speculate that Bifidobacterium supplementation or Bifidobacterium-
targeted diet may raise the threshold for autoimmune responses in 
patients with AIH. Since the standard therapy of AIH is burdened by 
complications of long-term immunosuppression and corticosteroid 
use, such novel therapeutic avenues would represent an attractive 
alternative. However, more data on the potential functional role of 
Bifidobacterium and strain-specific characteristics in AIH are clearly 
required.
AIH patients receiving azathioprine, a thiopurine class drug, 
had on average a higher microbial diversity compared to patients 
without azathioprine treatment—independently of parameters of 
disease activity or stage. Although azathioprine is the mainstay 
for maintenance of remission in AIH, the precise mechanism of 
action in AIH is still unclear. Thiopurines can modulate gut mi-
crobial composition and ameliorate colitis without entering the 
systemic circulation.32 Therefore, the beneficial effects of aza-
thioprine in AIH may in part be related to the modulation of gut 
microbiota and intestinal homeostasis. We could not detect sig-
nificant associations between microbial features and histological 
parameters. However, the major limitation here is the time gap of 
months to several years between liver biopsy and the time point 
of faecal sample collection in our cohort, as both features of in-
flammation and fibrosis tend to regress in AIH patients under im-
munosuppressive treatment.2
Our study has strengths and limitations that should be ad-
dressed by future studies. First, 16S-based analyses represent an 
important first step to detect microbial alterations in human dis-
eases. However, shotgun sequencing for metagenomics facilitates 
more accurate taxonomic information and functional insights. 
Second, the enteric mucosal microbiota was not analysed in the 
present study. Since stool samples cannot fully reflect the diver-
sity of mucosal communities, future studies should investigate 
mucosal microbiota in order to complete the landscape of enteric 
microbiota alterations in AIH. Third, untreated patients were not 
included in our study. Whereas this may introduce confounding by 
medication, unspecific inflammation-induced changes in untreated 
AIH patients were thus circumvented. A notable strength of our 
study is the comprehensive control for potential confounding by 
diet and other important lifestyle and clinical variables, and thor-
ough assessment of disease specificity using another autoimmune 
liver disease and a nonhepatic immune-mediated disease. Our 
results show significant accordance with the previous work pub-
lished by Wei et al5 To which extent the observed discrepancies, 
especially with regard to alterations of Bifidobacterium abundance, 
are related to amplicon-sequencing inherent bias, discordance in 
sequencing protocols, differences in disease duration, treatment 
or even dietary differences between Germany and China currently 
cannot be answered. Direct comparisons of larger international co-
horts are required to validate disease-specific microbial signatures 
in AIH independent from varying dietary and geodemographic 
circumstances.
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